Cytoplasmic translocation of MTA1 coregulator promotes de-repression of SGK1 transcription in hypoxic cancer cells

Oncogene
H MarzookM Radhakrishna Pillai

Abstract

Chromatin remodeling factor metastatic tumor protein 1 (MTA1), one of the most upregulated oncogene in human cancer, has an important role in gene expression, cell survival and promoting hypoxic response. Successful cancer progression is dependent on the ability of cells to utilize its survival pathways for adapting to hypoxic microenvironment. Although MTA1 is a stress-responsive gene, but whether hypoxia modulates its function and its role in engaging other core stress-responsive survival pathway(s) remains unknown. Here we have discovered that MTA1 is a novel corepressor of serum and glucocorticoid-inducible kinase 1 (SGK1). Surprisingly, this regulatory corepressive function of MTA1 is lost under hypoxia, allowing upregulation of SGK1 expression and engaging the MTA1-SGK1 axis for the benefit of the cell survival. The underlying mechanism of the noticed stimulation of SGK1 expression by hypoxia includes de-repression of SGK1 transcription because of hypoxia-triggered nucleus-to-cytoplasmic translocation of MTA1. In addition, the newly recognized cytoplasmic translocation of MTA1 was dependent on the chaperoning function of heat shock protein 90 (HSP90) and co-accompanied by the formation of MTA1, HSP90 and HIF1α complex und...Continue Reading

References

Mar 21, 2002·Nature Reviews. Cancer·Adrian L Harris
Oct 12, 2002·American Journal of Physiology. Endocrinology and Metabolism·Omar A ItaniChristie P Thomas
Jan 28, 2003·The American Journal of Pathology·Thomas J GiordanoSamir M Hanash
Sep 6, 2005·Proceedings of the National Academy of Sciences of the United States of America·Lance D MillerJonas Bergh
Feb 26, 2008·Mutation Research·Amber Buescher JohnsonMichelle Craig Barton
Apr 28, 2009·BMC Medical Genomics·Hideaki MizunoAkinori Sarai
Nov 17, 2009·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Krisztina RusaiJens Lutz
Apr 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Torsten HaferlachRobin Foà
Jun 15, 2010·The International Journal of Biochemistry & Cell Biology·Florian LangChristos Stournaras
May 25, 2011·Nature Reviews. Cancer·William R Wilson, Michael P Hay
May 23, 2012·Genome Research·Suhaida A SelamatIte A Laird-Offringa
Jul 4, 2012·Cancer Research·Bryan NewmanYin Wang
Apr 4, 2013·Science Signaling·Jianjiong GaoNikolaus Schultz
Apr 9, 2013·International Journal of Cancer. Journal International Du Cancer·Ya-Ping Tsai, Kou-Juey Wu
Apr 13, 2013·Cancer Research·Suresh B PakalaRakesh Kumar
May 8, 2013·Proceedings of the National Academy of Sciences of the United States of America·Christoph AnackerCarmine M Pariante
Apr 1, 2012·Hormones : International Journal of Endocrinology and Metabolism·Florian Lang, Christos Stournaras
May 16, 2014·International Journal of Cancer. Journal International Du Cancer·Chi ZhangYing Xu
Jun 3, 2014·The Canadian Journal of Cardiology·Binhai CongXin Ni
Oct 27, 2014·Cancer Metastasis Reviews·Nirmalya SenRakesh Kumar
Nov 16, 2014·Cancer Metastasis Reviews·Jian LiuHaili Qian
Jun 17, 2015·Biochimica Et Biophysica Acta·Gregg L Semenza
Jun 22, 2015·Advances in Cancer Research·Da-Qiang Li, Rakesh Kumar
Sep 25, 2015·Cells·Achim DickmannsRalf Ficner
Feb 13, 2016·Gene·Rakesh Kumar, Rui-An Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.